1. Multimodal and Multiscale Deep Neural Networks for the Early Diagnosis of Alzheimer’s Disease using structural MR and FDG-PET images
- Author
-
Lu, Donghuan, Popuri, Karteek, Ding, Gavin Weiguang, Balachandar, Rakesh, Beg, Mirza Faisal, and Alzheimer’s Disease Neuroimaging Initiative
- Subjects
Information and Computing Sciences ,Biochemistry and Cell Biology ,Biological Sciences ,Neurodegenerative ,Aging ,Prevention ,Alzheimer's Disease ,Neurosciences ,Dementia ,Brain Disorders ,Bioengineering ,Biomedical Imaging ,Acquired Cognitive Impairment ,Machine Learning and Artificial Intelligence ,Networking and Information Technology R&D (NITRD) ,Clinical Research ,Alzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD) ,4.1 Discovery and preclinical testing of markers and technologies ,4.2 Evaluation of markers and technologies ,Neurological ,Aged ,Aged ,80 and over ,Alzheimer Disease ,Brain ,Case-Control Studies ,Cognitive Dysfunction ,Deep Learning ,Early Diagnosis ,Fluorodeoxyglucose F18 ,Humans ,Magnetic Resonance Imaging ,Middle Aged ,Multimodal Imaging ,Neural Networks ,Computer ,Positron-Emission Tomography ,Radiopharmaceuticals ,Sensitivity and Specificity ,Alzheimer’s Disease Neuroimaging Initiative - Abstract
Alzheimer's Disease (AD) is a progressive neurodegenerative disease where biomarkers for disease based on pathophysiology may be able to provide objective measures for disease diagnosis and staging. Neuroimaging scans acquired from MRI and metabolism images obtained by FDG-PET provide in-vivo measurements of structure and function (glucose metabolism) in a living brain. It is hypothesized that combining multiple different image modalities providing complementary information could help improve early diagnosis of AD. In this paper, we propose a novel deep-learning-based framework to discriminate individuals with AD utilizing a multimodal and multiscale deep neural network. Our method delivers 82.4% accuracy in identifying the individuals with mild cognitive impairment (MCI) who will convert to AD at 3 years prior to conversion (86.4% combined accuracy for conversion within 1-3 years), a 94.23% sensitivity in classifying individuals with clinical diagnosis of probable AD, and a 86.3% specificity in classifying non-demented controls improving upon results in published literature.
- Published
- 2018